HIM
ALXN

Hillsdale Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Hillsdale Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-70
Closed -$11K – 712
2020
Q4 		$11K Sell
70
-4,500
-98% -$578K ﹤0.01% 492
2020
Q3 		$523K Buy
4,570
+100
+2% +$10.8K 0.05% 308
2020
Q2 		$502K Hold
4,470
– – 0.05% 318
2020
Q1 		$401K Buy
4,470
+100
+2% +$9.81K 0.05% 329
2019
Q4 		$473K Hold
4,370
– – 0.04% 374
2019
Q3 		$428K Buy
+4,370
New +$493K 0.04% 383
2018
Q1 		– Sell
-3,000
Closed -$359K – 552
2017
Q4 		$359K Buy
+3,000
New +$365K 0.06% 268
2015
Q2 		– Sell
-510
Closed -$88K – 571
2015
Q1 		$88K Sell
510
-1,400
-73% -$253K 0.02% 420
2014
Q4 		$353K Sell
1,910
-100
-5% -$18.5K 0.09% 191
2014
Q3 		$333K Hold
2,010
– – 0.11% 157
2014
Q2 		$314K Buy
2,010
+510
+34% +$80.5K 0.07% 203
2014
Q1 		$228K Buy
+1,500
New +$239K 0.06% 287

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hillsdale Investment Management's ALXN Position: Q1 2021 in Review

Hillsdale Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 70 shares — an estimated $11K sold.

Hillsdale Investment Management first reported a position in ALXN in Q1 2014 and held it in 12 quarters. The position peaked at $523K in Q3 2020. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Hillsdale Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Hillsdale Investment Management sold 70 Alexion Pharmaceuticals shares in Q1 2021, an estimated $11K.
  • Hillsdale Investment Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • Hillsdale Investment Management's Alexion Pharmaceuticals position peaked at $523K in Q3 2020.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Hillsdale Investment Management's 13F filing for Q1 2021, filed 22 Apr 2021.